Cover Image
市場調查報告書

呼吸抑制的開發中產品分析

Respiratory Depression - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 192804
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
呼吸抑制的開發中產品分析 Respiratory Depression - Pipeline Review, H2 2015
出版日期: 2015年09月30日 內容資訊: 英文 40 Pages
簡介

所謂呼吸抑制指的是呼吸障礙狀態──無法吸取充足的氧量,排出二氧化碳能力低落的狀態。其結果造成頻繁窒息、有胸部揪緊般的感覺。致病的危險因子有呼吸疾病和使用Opioids(類鴉片物質)等各種可能的要素。Opioids(類鴉片物質)主要是治療疼痛,但卻會帶來呼吸抑制等各種可能的副作用。

本報告提供全球各國治療呼吸抑制用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

呼吸抑制概要

治療藥的開發

  • 呼吸抑制開發中產品:概要
  • 呼吸抑制開發中產品:比較分析

各企業開發中的呼吸抑制治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段的產品

呼吸抑制治療藥:開發中的產品一覽(各企業)

呼吸抑制治療藥的開發企業

  • Cortex Pharmaceuticals, Inc.
  • Galleon Pharmaceuticals

呼吸抑制:治療藥的評估

  • 單劑治療藥的情況
  • 標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • CX-1739
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • GAL-021
  • CX-1942
  • CX-2007
  • CX-2076
  • GAL-021
  • Successors
  • doxapram hydrochloride
  • CX-1739

呼吸抑制治療藥:開發中產品的最新趨勢

呼吸抑制治療藥:開發暫停的產品

呼吸抑制相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全5件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7178IDB

Summary

Global Markets Direct's, 'Respiratory Depression - Pipeline Review, H2 2015', provides an overview of the Respiratory Depression's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Respiratory Depression
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Respiratory Depression and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Respiratory Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Respiratory Depression pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Respiratory Depression
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Respiratory Depression pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Respiratory Depression Overview
  • Therapeutics Development
    • Pipeline Products for Respiratory Depression - Overview
    • Pipeline Products for Respiratory Depression - Comparative Analysis
  • Respiratory Depression - Therapeutics under Development by Companies
  • Respiratory Depression - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Respiratory Depression - Products under Development by Companies
  • Respiratory Depression - Companies Involved in Therapeutics Development
    • Cortex Pharmaceuticals, Inc.
    • Galleon Pharmaceuticals
  • Respiratory Depression - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CX-1739 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-1942 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-2007 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-2076 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GAL-021 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tianeptine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Respiratory Depression - Recent Pipeline Updates
  • Respiratory Depression - Dormant Projects
  • Respiratory Depression - Product Development Milestones
    • Featured News & Press Releases
      • May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders
      • Sep 24, 2014: Cortex Pharmaceuticals Announces Phase 1 Funding by the National Institute of Drug Abuse, National Institutes of Health, Under the Small Business Innovation Research Funding Award Program
      • Feb 12, 2014: Revive Therapeutics Announces Encouraging Interim Results from Ongoing Phase 2a Proof-Of-Concept Study of REV-001 for the Prevention of Opioid-Induced Respiratory Depression
      • Sep 20, 2012: Galleon Pharma Reports Positive Results From Second Phase I Study Of GAL-021 For Treatment Of Respiratory Depression
      • May 07, 2012: Galleon Reports Positive Results From Phase I Study Of GAL-021 For Treatment Of Respiratory Depression
      • Aug 24, 2011: Cortex Receives US Patent For Use Of Ampakine Molecules To Treat Respiratory Depression
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Respiratory Depression, H2 2015
  • Number of Products under Development for Respiratory Depression - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Respiratory Depression - Pipeline by Cortex Pharmaceuticals, Inc., H2 2015
  • Respiratory Depression - Pipeline by Galleon Pharmaceuticals, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Respiratory Depression Therapeutics - Recent Pipeline Updates, H2 2015
  • Respiratory Depression - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Respiratory Depression, H2 2015
  • Number of Products under Development for Respiratory Depression - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top